WOIPPY, France--(BUSINESS WIRE)--Regulatory\u00a0News:<\/p>
\nABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorit\u00e9 des march\u00e9s financiers (AMF).<\/p>
\nThe report can be consulted on the ABL Diagnostics website: https:\/\/www.abldiagnostics.com<\/a> under the section \u201cNewsroom \u2013 Legal & Financial News\u201d.<\/p> \nThe Board of Directors, which met on April 30, 2025, approved the annual financial statements and decided to convene the shareholders to an Ordinary and Extraordinary General Meeting on June 30, 2026 at 11:00 a.m. at the offices of the law firm De Gaulle Fleurance & Associ\u00e9s, located at 9 rue Boissy d\u2019Anglas, 75008 Paris.<\/p> \nAbout ABL Diagnostics (ABLD)<\/b><\/p> \nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p> \nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p> \nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p> \nAn expanding portfolio of microbiology products:<\/b><\/p> \nIntegrated Solutions<\/b><\/p> \nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p> \nABL Diagnostics SA<\/b> \nTel : +33 (0)7 83 64 68 50\n WOIPPY, France–(BUSINESS WIRE)–Regulatory\u00a0News:\n
\n
\n
\nABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorit\u00e9 des march\u00e9s financiers (AMF).
\nThe report can be consulted …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2673","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2673"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2673\/revisions"}],"predecessor-version":[{"id":2674,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2673\/revisions\/2674"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}